

Bridgewest to acquire Pfizer's injectable manufacturing plant in Australia

11 November 2022 | News

The facility has extensive blow fill seal capabilities for producing sterile injectable essential drug products

US-based Bridgewest Group has announced the signing of a definitive agreement to purchase the sterile injectable manufacturing facility of Pfizer (Perth), a subsidiary of Pfizer, Inc.

The cGMP manufacturing facility, located in Bentley, a Perth suburb in Western Australia, is a diverse sterile injectable manufacturing facility, approved to supply drug products in over 90 countries globally with approvals secured by regulatory bodies including the FDA, TGA, EU and others.

The facility has extensive blow fill seal (BFS) capabilities for producing sterile injectable essential drug products as well as significant capabilities to produce specialty oncology drug products for global distribution. In addition to the operations and facility, Bridgewest Group will also be acquiring a suite of drug products from Pfizer which it will look to aggressively market and expand globally.

In 2020, Bridgewest Group successfully acquired Hospira Adelaide, a microbial drug substance manufacturer in Adelaide, which it now operates under the name BioCina.

BioCina has been operating as a contract development manufacturing organization (CDMO) and has had great success since taking over from Pfizer, growing its employee base in Adelaide by 30% and adding numerous customers from around the world. Since Bridgewest Group's acquisition, BioCina has upgraded the Adelaide site to include pDNA and mRNA manufacturing capabilities. The Perth operation will be a separate and distinct business from BioCina.